Intranasal nanotherapeutics for brain targeting and clinical studies in Parkinson's disease

P Saha, H Kathuria, MM Pandey - Journal of Controlled Release, 2023 - Elsevier
Parkinson's disease (PD) is the second leading neurodegenerative disease globally,
impacting the quality of life of millions of people. It is estimated that the treatment cost of PD …

Mechanistic approaches to predicting oral drug absorption

W Huang, SL Lee, LX Yu - The AAPS journal, 2009 - Springer
Modeling and simulation of oral drug absorption have been widely used in drug discovery,
development, and regulation. Predictive absorption models are used to determine the rate …

[图书][B] Controlled drug delivery: fundamentals and applications

J Robinson, VHL Lee - 1987 - api.taylorfrancis.com
Controlled Drug Delivery Page 1 Controlled Drug Delivery Page 2 DRUGS AND THE
PHARMACEUTICAL SCIENCES A Series of Textbooks and Monographs Edited by James …

[HTML][HTML] Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships

C Louizos, JA Yáñez, L Forrest… - Journal of pharmacy & …, 2014 - ncbi.nlm.nih.gov
Hysteresis loops are phenomena that sometimes are encountered in the analysis of
pharmacokinetic and pharmacodynamic relationships spanning from pre-clinical to clinical …

Evaluation of rat intestinal absorption data and correlation with human intestinal absorption

YH Zhao, MH Abraham, J Le, A Hersey… - European journal of …, 2003 - Elsevier
The absorption of 111 drug and drug-like compounds was evaluated from 111 references
based on the ratio of urinary excretion of drugs following oral and intravenous administration …

Physiological manifestations of endophyte toxicosis in ruminant and laboratory species

JW Oliver - Neotyphodium/grass interactions, 1997 - Springer
Fescue alkaloid intake by cattle results in adverse metabolic effects that cause billion dollar
losses annually to livestock production in the US alone (Bacon et al., 1977; Garner and …

Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters

S Luo, Y Liang, AH Cincotta - Neuroendocrinology, 1999 - karger.com
Bromocriptine, a potent dopamine D 2 receptor agonist, suppresses lipogenesis and
improves glucose intolerance and insulin resistance. Recent evidence suggests that …

Interactions between the dopamine agonist, bromocriptine and the efflux protein, P-glycoprotein at the blood–brain barrier in the mouse

S Vautier, L Lacomblez, H Chacun, V Picard… - European journal of …, 2006 - Elsevier
Bromocriptin (BCT) is a dopaminergic receptor agonist, poorly transported through the blood–
brain barrier (BBB) and responsible for central side effects. Interactions between BCT and …

Nanomedicine for Maternal and Fetal Health

D Carter, M Better, S Abbasi, F Zulfiqar, R Shapiro… - Small, 2023 - Wiley Online Library
Conception, pregnancy, and childbirth are complex processes that affect both mother and
fetus. Thus, it is perhaps not surprising that in the United States alone, roughly 11% of …

Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animals and humans

H Wachtel - Journal of neural transmission-Parkinson's disease …, 1991 - Springer
With the intention of compensating for the deficit of endogenous dopamine (DA) in the basal
ganglia of Parkinsonian patients by substitution with agents which directly stimulate central …